urothelial carcinoma (advanced)

systematic review meta-analysis network meta-analysis

Select immune checkpoint inhibition All type of patient       anti-PD-1PD-L1 inhibitors atezolizumabavelumab durvalumabnivolumabpembrolizumab vs chemotherapyvs placebo or control       1st line2nd line

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	death (overall survival) (2)progression or death (progression free survival PFS) (1)objective response (ORR) (1)Grade 3–5 drug-related AEs (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	death (overall survival)	progression or death (progression free survival PFS)
immune checkpoint inhibition
atezolizumab
IMvigor211 (IC2/3)      NCT	atezolizumab	chemotherapy	2nd line, IC2/3	2nd line	Risk of bias	suggesting
IMVIGOR-130 (monotherapy)    NCT	atezolizumab	control	first line	1st line	Risk of bias	remark
IMvigor210 single-arm      NCT	atezolizumab	nil	1st and 2nd line	1st line 2nd line	Exploratory	-
durvalumab
durvalumab phase 1/2 single-arm	durvalumab	nil	2nd line	2nd line	Exploratory	-
nivolumab
Checkmate 275 single-arm      NCT	nivolumab	nil	2nd line	2nd line	Exploratory	-
pembrolizumab
KEYNOTE-052, 2017 single-arm      NCT	pembrolizumab			1st line	Risk of bias	-
KEYNOTE-045, 2017    NCT	pembrolizumab	chemotherapy	2nd line	2nd line	Risk of bias	suggesting
Keynote 361 monotherapy    NCT	pembrolizumab	chemotherapy	first line			remark